Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 2.

Mechanisms induced by rosmarinic acid in different cancer models (in-vivo)

Cancer type Animal models Treatment concentrations Mechanism of action References
HCC H22-xenograft mice 75, 150 and 300 mg/kg Inhibition of NF-κB p65 Cao et al., 2016
SMMC-7721 inoculated mice 0, 5, 10 and 20 mg/kg Inhibition of PI3K/AKT pathway Wang et al., 2019, 2021
CRC DMH-induced rat 4, 8 and 16 mg/kg Antioxidant activity by acting on cytochrome P450 Furtado et al., 2015
DMH-induced rat 5 mg/kg Venkatachalam et al., 2016
AOM/DSS-induced CAC mice 30 mg/kg Suppression of TLR4-mediated NF-κB and pSTAT3 Jin et al., 2021
Pancreatic cancer Panc-1 inoculated mice

10 mg/kg

50 mg/kg

Elevated expression of miR-506 Han et al., 2019; Zhou et al., 2022
PDAC xenograft mice 50 mg/kg Inhibition of Gli1 expression Zhou et al., 2022
Breast cancer Ehrlich induced mice 50 and 100 mg/kg Impeding NF-κB-p53-Caspase-3 pathway Mahmoud et al., 2021
Gastric cancer MKN45 inoculated mice 2 mg/kg Inhibition of Warburg effect Han et al., 2015
Biomolecules & Therapeutics 2024;32:38~55 https://doi.org/10.4062/biomolther.2023.054
© Biomolecules & Therapeutics